Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525160 | 1.00 | CHRM4 (0.49) | CHRM4CXCR3BRD4HDAC3HDAC1 | |
| SCHEMBL5526242 | 0.84 | CXCR3 (0.54) | CHRM4CXCR3 | |
| SCHEMBL5526237 | 0.84 | CXCR3 (0.54) | CHRM4CXCR3 | |
| SCHEMBL5516045 | 0.83 | CXCR3 (0.60) | CHRM4CXCR3 | |
| SCHEMBL5516047 | 0.83 | CXCR3 (0.60) | CHRM4CXCR3 | |
| SCHEMBL5522632 | 0.81 | CXCR3 (0.55) | CHRM4CXCR3BRD4HDAC3HDAC1 | |
| SCHEMBL5522636 | 0.81 | CXCR3 (0.55) | CHRM4CXCR3BRD4HDAC3HDAC1 | |
| SCHEMBL6392396 | 0.75 | CXCR4 (0.47) | HDAC3HDAC1HDAC2 | |
| SCHEMBL5521812 | 0.74 | HDAC3 (0.51) | CHRM4CXCR3HDAC3HDAC1HDAC2 | |
| SCHEMBL5523321 | 0.74 | HDAC3 (0.51) | CHRM4CXCR3HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | CHRM4 1218/4885CXCR3 2070/4885BRD4 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.